News Releases

 
News Releases
  Date Title and Summary View
Jan 5, 2006
Mountain View, CA; January 5, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced the appointment of Susan M. Kanaya to the post of Senior Vice President, Finance and Chief Financi...
Nov 22, 2005
Mountain View, CA; November 22, 2005 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, announced that the company has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Ad...
May 16, 2005
Chicago, IL; May 16, 2005 — ChemoCentryx, Inc. presented positive Phase 1 clinical and preclinical data from studies of the company's lead product for inflammatory bowel disease (IBD), Traficet-EN™ (CCX282) at the Digestive Disease Week 2005 conference being held in Chicago, Illinois May 14-19, 2005. These data indica...
Jan 6, 2005
January 6, 2005; Mountain View, Calif. — ChemoCentryx, Inc. today announced that the company is currently conducting a Phase II clinical trial to evaluate the safety and pharmacokinetics of one of the company's lead products, Traficet-EN™ (CCX282), among patients with inflammatory bowel disease (IBD). ...
Jun 17, 2004
June 17, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has closed a private financing round raising gross proceeds of $33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round. Additional participants included new investors GIMV and Hanseatic, as well as returning investors...
Mar 15, 2004
March 15, 2004; San Carlos, CA and New York, NY — ChemoCentryx, Inc., a privately held focused pharmaceutical company, and Forest Laboratories, Inc. (NYSE: FRX) announced today that the two companies have entered into a collaboration agreement to develop and commercialize novel small molecule therapeutics for autoimmune and inflammator...
Jan 13, 2004
January 13, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has initiated a Phase I clinical trial to evaluate its novel drug candidate for the treatment of inflammatory bowel disease (IBD). The compound, known as Traficet-EN™, is a novel, orally active anti-inflammatory agent that targets a chem...
Oct 13, 2003
October 13, 2003; San Carlos, Calif. — ChemoCentryx, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded the company a $14 million grant to develop first-in-class immune modulatory agents targeting chemokine receptors for the prevention and ...
Sep 17, 2002
September 17, 2002; San Carlos, Calif. — ChemoCentryx, Inc. today announced the initiation of a Phase I clinical trial in the United Kingdom by its partner, Tularik Inc., (Nasdaq: TLRK), for T487, an oral anti-inflammatory drug candidate. T487 is the most advanced clinical candidate in ChemoCentryx's broad pipeline ...
Page: FirstPrevious ...
18
= add release to Briefcase